日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

HDAC inhibitor tucidinostat and metronomic capecitabine plus endocrine therapy for patients with HR-positive HER2-negative advanced breast cancer after CDK4/6 inhibitors treatment: clinical findings and exploratory circulating tumor cell and ctDNA biomarker analyses of a multicenter, phase 2 study (SYSUCC-020 trial)

HDAC抑制剂tucidinostat和节拍式卡培他滨联合内分泌治疗用于CDK4/6抑制剂治疗后HR阳性HER2阴性晚期乳腺癌患者:一项多中心2期研究的临床结果和探索性循环肿瘤细胞和ctDNA生物标志物分析(SYSUCC-020试验)

Wu, Huai-Liang; Xia, Wen; Xu, Zhengyang; Zhou, Hanxing; Chen, Limin; Lu, Yongkui; Liu, Xinlan; Pang, Danmei; Liu, Yan; Lu, Qianyi; Xu, Fei; An, Xin; Huang, Jiajia; Jiang, Kuikui; Zhang, Jingmin; Cai, Yili; Hong, Ruoxi; Zheng, Qiufan; Wang, Shusen

Pyrotinib or placebo in combination with trastuzumab and docetaxel for HER2 positive metastatic breast cancer: long term survival results from randomised phase 3 PHILA trial

吡咯替尼或安慰剂联合曲妥珠单抗和多西他赛治疗HER2阳性转移性乳腺癌:随机3期PHILA试验的长期生存结果

Ma, Fei; Yan, Min; Li, Wei; Ouyang, Quchang; Tong, Zhongsheng; Teng, Yuee; Wang, Yongsheng; Wang, Shusen; Geng, Cuizhi; Luo, Ting; Zhong, Jincai; Zhang, Qingyuan; Liu, Qiang; Zeng, Xiaohua; Sun, Tao; Mo, Qinguo; Zhou, Shoubing; Li, Peidong; Cheng, Jing; Wang, Xiaojia; Nie, Jianyun; Yang, Jin; Wu, Xinhong; Wang, Xinshuai; Li, Huiping; Yao, Guangyu; Fan, Yang; Lin, Jiaman; Zhu, Xiaoyu; Xu, Binghe

Corrigendum to "Cu(II)-baicalein enhance paracrine effect and regenerative function of stem cells in patients with diabetes"

关于“Cu(II)-黄芩苷增强糖尿病患者干细胞的旁分泌效应和再生功能”的更正

Liu, Kaijing; Li, Ruihao; Wang, Shusen; Fu, Xue; Zhu, Ni; Liang, Xiaoyu; Li, Huiyang; Wang, Xiaoli; Wang, Le; Li, Yongjun; Dai, Jianwu; Yang, Jing

Redistribution of super-enhancers promotes malignancy in human hepatocellular carcinoma.

超级增强子的重新分布促进了人类肝细胞癌的恶性进展。

Huang Jiacheng, Xu Liang, Chen Ye, Sun Mengqing, Hu Yiqing, Pan Caixu, Jiang Liangyu, Wang Menglan, Liu Jing, Dong Heng, Li Qian, Bu Fangtian, Chang Cunjie, Chen Xuliang, Wang Yu, Zheng Shusen, Ling Qi, Chen Jianxiang, Qiao Yiting

Macrophage-delivered Nifuroxazide reprograms immunosuppressive microenvironment and synergizes with oxaliplatin for enhanced anti-hepatocellular carcinoma therapy.

巨噬细胞递送的尼呋罗嗪可重编程免疫抑制微环境,并与奥沙利铂协同作用,增强抗肝细胞癌治疗效果。

Yang Zhentao, Tang Hong, Wang Ning, Sun Ruiqi, Zhou Ke, Zhao Wentao, Liang Zhi, Ma Haojing, Li Haoyu, Song Penghong, Tu Zhengliang, Zheng Shusen, Xie Haiyang

Micro-Petal Cobalt-Doped FeMoB Framework for Efficient Hydrogen Generation in Ampere-Level Water Electrolysis

用于安培级水电解中高效制氢的微瓣钴掺杂FeMoB框架

Joni, Mehedi Hasan; Dristy, Sumiya Akter; Najibullah, Md; Habib, Md Ahasan; Lin, Shusen; Lee, Jihoon

Oncolytic virotherapy potentiates chemo-PD-1 immunotherapy by engaging chemo-resistant bystander CD8(+) T cells.

溶瘤病毒疗法通过激活耐药的旁观者 CD8(+) T 细胞来增强化疗-PD-1 免疫疗法的效果。

Yang Yang, He Junjian, Liang Texi, Li Kaiyi, Lin Yao, Wang Hairu, Xi Wenwen, Ye Shusen, Qiu Ding, Xie Chunyang, Hao Yaxing, Li Teming, Yue Shuai, Ye Lilin, Chen Xiangyu

Designing adhesive hydrogels for oral diseases treatment

设计用于治疗口腔疾病的粘附性水凝胶

Peng, Yufei; Jiang, Zhisheng; Xu, Shusen; He, Liming; Jiang, Tong; Yang, Yujie; Xie, Xiaoyan; Lei, Lanjie

Extracellular matrix-derived mechanical force induces CDK4/6 inhibitor resistance by inhibiting NEK10 dependent cell cycle regulation in breast cancer

细胞外基质衍生的机械力通过抑制NEK10依赖的细胞周期调控,诱导乳腺癌细胞产生CDK4/6抑制剂耐药性。

Li, Cong; Wang, Jian; Jin, Yuming; Huang, Yumeng; Hong, Ruoxi; Chen, Dongshao; Lin, Shaoyan; Chen, Limin; Wu, Huailiang; Du, Ting; Xu, Binghe; Wang, Wan; Wang, Shusen

NPLOC4 Inhibition Remodels Tumor Microenvironment via M2-to-M1 Macrophage Reprogramming and Boosts Anti-PD-1 Response in Liver Cancer

NPLOC4抑制通过M2向M1巨噬细胞重编程重塑肿瘤微环境并增强肝癌中的抗PD-1反应

Gao, Xingxing; Huang, Hechen; Pan, Caixu; Huang, Jiacheng; Chen, Junru; Yin, Shengyong; Zhou, Lin; Zheng, Shusen